The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Iron Chelation Drug-Global Market Insights and Sales Trends 2025
Synopsis
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
The global Iron Chelation Drug market size is expected to reach US$ 430.7 million by 2029, growing at a CAGR of -6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Iron Chelation Drug in various end use industries. The expanding demands from the Transfusional Iron Overload and NTDT Caused Iron Overload, are propelling Iron Chelation Drug market. Deferasirox, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Deferoxamine segment is estimated at % CAGR for the next seven-year period.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Iron Chelation Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Iron Chelation Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Iron Chelation Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Iron Chelation Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Iron Chelation Drug covered in this report include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, Taro Pharm and Gland Pharma, etc.
The global Iron Chelation Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Global Iron Chelation Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Iron Chelation Drug market, Segment by Type:
Deferasirox
Deferoxamine
Deferiprone
Global Iron Chelation Drug market, by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Iron Chelation Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Iron Chelation Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
The global Iron Chelation Drug market size is expected to reach US$ 430.7 million by 2029, growing at a CAGR of -6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Iron Chelation Drug in various end use industries. The expanding demands from the Transfusional Iron Overload and NTDT Caused Iron Overload, are propelling Iron Chelation Drug market. Deferasirox, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Deferoxamine segment is estimated at % CAGR for the next seven-year period.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Iron Chelation Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Iron Chelation Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Iron Chelation Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Iron Chelation Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Iron Chelation Drug covered in this report include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, Taro Pharm and Gland Pharma, etc.
The global Iron Chelation Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Global Iron Chelation Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Iron Chelation Drug market, Segment by Type:
Deferasirox
Deferoxamine
Deferiprone
Global Iron Chelation Drug market, by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Iron Chelation Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Iron Chelation Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Iron Chelation Drug Market Overview
1.1 Iron Chelation Drug Product Overview
1.2 Iron Chelation Drug Market Segment by Type
1.2.1 Deferasirox
1.2.2 Deferoxamine
1.2.3 Deferiprone
1.3 Global Iron Chelation Drug Market Size by Type
1.3.1 Global Iron Chelation Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Iron Chelation Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Iron Chelation Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Iron Chelation Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Iron Chelation Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Iron Chelation Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Iron Chelation Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Iron Chelation Drug Sales Breakdown by Type (2018-2023)
2 Global Iron Chelation Drug Market Competition by Company
2.1 Global Top Players by Iron Chelation Drug Sales (2018-2023)
2.2 Global Top Players by Iron Chelation Drug Revenue (2018-2023)
2.3 Global Top Players by Iron Chelation Drug Price (2018-2023)
2.4 Global Top Manufacturers Iron Chelation Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Iron Chelation Drug Market Competitive Situation and Trends
2.5.1 Iron Chelation Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Iron Chelation Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Iron Chelation Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Iron Chelation Drug Market
2.8 Key Manufacturers Iron Chelation Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Iron Chelation Drug Status and Outlook by Region
3.1 Global Iron Chelation Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Iron Chelation Drug Historic Market Size by Region
3.2.1 Global Iron Chelation Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Iron Chelation Drug Sales in Value by Region (2018-2023)
3.2.3 Global Iron Chelation Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Iron Chelation Drug Forecasted Market Size by Region
3.3.1 Global Iron Chelation Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Iron Chelation Drug Sales in Value by Region (2024-2029)
3.3.3 Global Iron Chelation Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Iron Chelation Drug by Application
4.1 Iron Chelation Drug Market Segment by Application
4.1.1 Transfusional Iron Overload
4.1.2 NTDT Caused Iron Overload
4.2 Global Iron Chelation Drug Market Size by Application
4.2.1 Global Iron Chelation Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Iron Chelation Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Iron Chelation Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Iron Chelation Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Iron Chelation Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Iron Chelation Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Iron Chelation Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Iron Chelation Drug Sales Breakdown by Application (2018-2023)
5 North America Iron Chelation Drug by Country
5.1 North America Iron Chelation Drug Historic Market Size by Country
5.1.1 North America Iron Chelation Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Iron Chelation Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Iron Chelation Drug Sales in Value by Country (2018-2023)
5.2 North America Iron Chelation Drug Forecasted Market Size by Country
5.2.1 North America Iron Chelation Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Iron Chelation Drug Sales in Value by Country (2024-2029)
6 Europe Iron Chelation Drug by Country
6.1 Europe Iron Chelation Drug Historic Market Size by Country
6.1.1 Europe Iron Chelation Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Iron Chelation Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Iron Chelation Drug Sales in Value by Country (2018-2023)
6.2 Europe Iron Chelation Drug Forecasted Market Size by Country
6.2.1 Europe Iron Chelation Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Iron Chelation Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Iron Chelation Drug by Region
7.1 Asia-Pacific Iron Chelation Drug Historic Market Size by Region
7.1.1 Asia-Pacific Iron Chelation Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Iron Chelation Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Iron Chelation Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Iron Chelation Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Iron Chelation Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Iron Chelation Drug Sales in Value by Region (2024-2029)
8 Latin America Iron Chelation Drug by Country
8.1 Latin America Iron Chelation Drug Historic Market Size by Country
8.1.1 Latin America Iron Chelation Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Iron Chelation Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Iron Chelation Drug Sales in Value by Country (2018-2023)
8.2 Latin America Iron Chelation Drug Forecasted Market Size by Country
8.2.1 Latin America Iron Chelation Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Iron Chelation Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Iron Chelation Drug by Country
9.1 Middle East and Africa Iron Chelation Drug Historic Market Size by Country
9.1.1 Middle East and Africa Iron Chelation Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Iron Chelation Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Iron Chelation Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Iron Chelation Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Iron Chelation Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Iron Chelation Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Iron Chelation Drug Products Offered
10.1.5 Novartis Recent Development
10.2 Chiesi Group
10.2.1 Chiesi Group Company Information
10.2.2 Chiesi Group Introduction and Business Overview
10.2.3 Chiesi Group Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Chiesi Group Iron Chelation Drug Products Offered
10.2.5 Chiesi Group Recent Development
10.3 Sun Pharma
10.3.1 Sun Pharma Company Information
10.3.2 Sun Pharma Introduction and Business Overview
10.3.3 Sun Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sun Pharma Iron Chelation Drug Products Offered
10.3.5 Sun Pharma Recent Development
10.4 Cipla
10.4.1 Cipla Company Information
10.4.2 Cipla Introduction and Business Overview
10.4.3 Cipla Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Cipla Iron Chelation Drug Products Offered
10.4.5 Cipla Recent Development
10.5 Natco Pharma
10.5.1 Natco Pharma Company Information
10.5.2 Natco Pharma Introduction and Business Overview
10.5.3 Natco Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Natco Pharma Iron Chelation Drug Products Offered
10.5.5 Natco Pharma Recent Development
10.6 Taro Pharm
10.6.1 Taro Pharm Company Information
10.6.2 Taro Pharm Introduction and Business Overview
10.6.3 Taro Pharm Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Taro Pharm Iron Chelation Drug Products Offered
10.6.5 Taro Pharm Recent Development
10.7 Gland Pharma
10.7.1 Gland Pharma Company Information
10.7.2 Gland Pharma Introduction and Business Overview
10.7.3 Gland Pharma Iron Chelation Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Gland Pharma Iron Chelation Drug Products Offered
10.7.5 Gland Pharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Iron Chelation Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Iron Chelation Drug Industrial Chain Analysis
11.4 Iron Chelation Drug Market Dynamics
11.4.1 Iron Chelation Drug Industry Trends
11.4.2 Iron Chelation Drug Market Drivers
11.4.3 Iron Chelation Drug Market Challenges
11.4.4 Iron Chelation Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Iron Chelation Drug Distributors
12.3 Iron Chelation Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
